Amniotic membrane-based antimicrobial agent
Areas
Health
Fields of use
Healthcare-Medical Science
Current state of technology
Laboratory tested; preclinical
Intellectual property
Patent pending, LU101112
Developed by
University of Ljubljana, Medical Faculty
Reference
821-19/2018
Contact
Gabriela Droga Mazovec
Phone: +386 70 538 284
E-mail: gospodarstvo@uni-lj.si
Download PDF
- TO-Amniotic-membrane-based-antimicrobial-agent_EN.pdf (pdf, 354 KB)
Background
During the years 2000 and 2015, the use of antibiotics worldwide increased for 65%. Epidemiological studies showed the correlation between the increasing use of antibiotics and the emergence and spreading of bacteria, resistant to antibiotics. The studies show there is a great need for discovery and development of novel antimicrobials.
Description of invention
The developed mammalian amniotic membrane homogenate can be used as an antimicrobial agent. The preparation of which runs through a well-determined procedure so that its antibacterial characteristics remain intact.
Main advantages
Antimicrobial activity of amniotic membrane has been proven against several bacteria, namely Escherichia coli, Staphylococcus aureus, Enterobacter sp., Klebsiella pneumoniae, Staphylococcus saprophyticus and others. The preparation procedure is simple and cost-effective and the homogenate presents a high efficacy rate.